Studies of Fzd9 function show it to be upregulated in triple-negative breast cancer, but it is also tumor-suppressive in NSCLC (de Bastos et al., 2021), (Tennis et al., 2010). Here, FZD9 is linked to non-small cell lung carcinoma.